Today’s AI Top Pick: SPRO

7/22/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · ContrarianSPROBUY NOW8.8 / 107/22/2026

SPRO is the highest-conviction contrarian bounce here because it combines the strongest fundamental score in the pool (+8: PE 5.66, fwdPe 2.06, profitMargin 27.82%, salesYoY +93.5%, ROE 35.12%) with a fresh, hard positive catalyst — the July 15 announcement that Innovent licensed IBI355 rights to Spero for up to $1.1B, plus a Seeking Alpha 'Buy' the same week citing the Utebzi royalty deal for funding. That is exactly the kind of news that flips exhausted selling into a coiled bounce, and it lands right into a Kronos bullish_prob of 1.0 and near_term_bullish of 1.0. Multi-timeframe alignment is genuinely 'gold' quality: 1h forecast +91.5%, 4h +87.3%, 1d +42.4%, 1wk +48.1% — all four timeframes point up, mid/long horizons stay bullish (fc_long 83.2% on 1h, 77.0% on 4h, 55.3% on 1d). Position-in-21bar-range is 15.5% / 1.6% / 0% / 0%, i.e., it is not extended — you are not chasing. RSI 22.56 is deeply oversold, drawdown -27.2% over 14d with a -39% drop from the 21-bar daily high, so the setup fits 'exhausted seller' rather than 'still breaking down.' Expected return is ~35% with analyst targetUpsidePct of 189.9% and recom of 3 (which is the only real caution). Against the other 8-fund-score name, ALNY, Spero has a real news catalyst; ALNY's 1wk forecast actually turns negative (fc_mid -14.2%, fc_long -17.7%), which is a yellow flag. IBM has clean TF alignment but reports earnings today (Jul 22 headline: 'IBM Faces Its Biggest Earnings Test Yet After a Historic Stock Drop') — pure event risk, wrong day to add. ISRG is the safest large-cap alternative but only ~37% expected return and less asymmetric. Why TODAY: RSI 22.56, sitting at 0% of daily/weekly range, near-term forecast 1.0, and a $1.1B deal already announced but the stock still down ~40% YTD — the market has not repriced the catalyst yet. Waiting for a pullback risks missing the gap-and-go once shorts (6.69% float) start covering.

Entry zone

$1.35 - $1.42 (buy into weakness intraday; current $1.39)

Stop loss

$1.14 (below the 21-bar daily low, ~18% risk)

First target

$1.85 - $1.95 (33-40% move, aligned with 1h/4h fc_short of ~90%)

Longer target

$2.55 - $2.80 (roughly the 1d fc_mid +72% zone; deal-driven re-rate)

Risks

Small cap ($79.9M market cap) with 6.69% short float — liquidity gaps both directions
Analyst recom of 3.0 (Hold) despite fund_score 8 — Street is skeptical the Innovent/Utebzi deals fund a durable P&L
Weekly forecast decays: fc_long only +7.75% on 1wk vs +48% on fc_short — bounce may be tactical, not trend reversal
Biotech single-catalyst risk: any IBI355 or SP001 development slippage would kill the thesis
Broader biotech tape is soft (perfYtd -40.77%, perfYear -40.52%) — market could ignore stock-specific news

Honorable mentions

ISRGCleanest large-cap setup: fund_score 5.75, all TFs positive (1h +21%, 4h +25%, 1d +31%, 1wk +15%), position 48.6% on 1h and 0% on 1wk (not extended), 'multi-year lows / bargain' narrative in headlines. Lower expected return (~37%) but far lower blowup risk than SPRO.

ALNYTied best fund_score (+8) with PEG 0.31, ROE 96.94%, salesYoY 82.57%. TFs mostly up on 1h/4h/1d but 1wk forecast turns negative (-14 to -18%), so treat as a mean-reversion trade to $310-330 rather than a trend restart.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	SPRO	BUY NOW	8.8	Fund_score 8 + $1.1B Innovent licensing catalyst + all-TF bullish (fc 91%/87%/42%/48%) at 0% of daily range — the cleanest asymmetric setup in the pool.
2	ISRG	BUY NOW	8.0	Blue-chip med device at multi-year lows, all TFs up (+21/+25/+31/+15%), fund_score 5.75, 1wk at 0% of range — safest bounce in the pool.
3	ALNY	BUY NOW	7.4	Fund_score 8, PEG 0.31, ROE 96.9%; 1h/4h/1d forecasts up but 1wk turns negative — tactical rebound, not trend restart.
4	BESS	BUY PULLBACK	7.0	All TFs up hard (1d +45%, 1wk +58% short, +101% long), fund_score 6, but perfYtd -68.95% and thin liquidity — size small.
5	LEGN	BUY PULLBACK	6.5	Biotech with 1h at 100% of range (extended), 1wk fc +72%, RBC Outperform though PT lowered — wait for 4h reset.
6	AKTX	BUY PULLBACK	6.3	Maxim upgrade to Buy with $30 PT and 1d fc +46%, but 1h fc_long -39% signals near-term chop.
7	IBM	WAIT	6.2	TF alignment is clean (all up), but earnings report TODAY per headline — event risk trumps the setup; revisit post-print.
8	CRML	BUY PULLBACK	6.0	1h fc +75% and rare earth narrative, but Simply Wall St 'overvalued after asset review' and press release retraction are red flags.
9	OPTT	BUY PULLBACK	5.9	US gov selection catalyst + 1d fc +85%, but sub-$1 stock with salesYoY -43.84% and profitMargin -1048% is high-lottery.
10	GTBP	WAIT	5.7	Near_term_bullish only 0.2 despite bullish_prob 1; 1h fc weak (+6%) — signal quality mediocre.
11	CALC	BUY PULLBACK	5.6	FDA no-concerns on Auxora is real, 1d fc +219%, but $49M private placement is dilutive and 1h is at 87% of range.
12	TCRX	BUY PULLBACK	5.5	Wedbush/Needham buys with targets 4-5x current, salesYoY +107%, but 1h at 63% of range — not oversold.
13	GRRR	WAIT	5.4	$232M bond raise accelerates AI infra but dilution just crushed the stock -32% — let convert digestion play out.
14	IONQ	BUY PULLBACK	5.3	1h fc +47%, 4h +25%, RSI 29.14, but 1wk forecast NEGATIVE (fc_mid -37%) — bounce trade only.
15	ASPI	BUY PULLBACK	5.1	Noble Africa/helium catalyst and 1h fc +58%, but 1wk fc turns -25% and shortFloat 21.77% cuts both ways.
16	PCT	WAIT	4.8	Mitsui/RM TOHCELLO partnership positive, all TFs up, but ps 117.6 and debtEq 99.58 are extreme valuation/leverage.
17	RDW	WAIT	4.6	Space narrative + 1h fc +40%, but 1d fc_short is NEGATIVE (-7.76%) and 1wk fc_long -10.95% — model losing conviction.
18	QBTS	AVOID	4.4	CEO sold 50k+ shares, 1wk fc -9% and beyond negative; ps 530 is nonsensical — pass.
19	INV	BUY PULLBACK	4.3	1h fc +88% and CEO transition Oct 1, but operMargin -3586% and 1h at 86% of range — chase risk.
20	ATYR	WAIT	4.2	Phase 3 sarcoidosis narrative alive but fund_score -3.25, ps 250, and perfYear -91.5% — binary event stock.
21	ANY	BUY PULLBACK	4.0	1d fc +140% and 53MW infra deals, but sub-$2 penny with -163% profit margin and name change signals reset.
22	SKIN	BUY PULLBACK	3.9	Zacks Strong Buy and FDA clearance on Skinstylus are real, but fund_score -1.75 and debtEq 6.65 cap upside.
23	ALEC	AVOID	3.7	GSK ended the brain drug alliance July 9 — thesis broken regardless of the +29% 1d forecast; salesYoY -79%.
24	LUCY	WAIT	3.6	Claude AI integration cute but $3M warrant exercise is fresh dilution, market cap $4.68M microcap.
25	RXRX	AVOID	3.4	Multiple 'fell more than market' headlines, shortFloat 36.62%, fund_score -3.5 — trend is still broken.
26	BIRD	AVOID	3.4	Post-rebrand euphoria fading, 1wk forecasts NEGATIVE (-27%), fund_score -3, salesYoY -21.8%.
27	LESL	AVOID	3.2	StockStory '3 Reasons to Avoid LESL', Hayward comps trading lower, fund_score -1, ps 0.02 hints at distress.
28	SST	WAIT	3.1	Big forecast numbers (1d fc +105%) but $17M market cap and salesYoY -31% — pure speculation.
29	DSY	AVOID	2.8	Fund_score -2.5, ROE -9117%, no analyst coverage; weekly fc of +714% is model noise, not a signal.
30	ILLR	AVOID	2.5	Company itself flagging stock volatility with no material development, ongoing dilution authorization issues — landmine.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord